The Company develops, manufactures and distributes life-science products that replicate the performance of human organ systems. The Company's main product, a proprietary fluidic culture system, improves pharmaceutical and biotechnology companies' ability to predict human responses to drug compounds that they are developing in a more in vivo-like fashion. This allows them to determine the toxicity and efficacy much earlier in the development cycle, potentially saving hundreds of millions of dollars in development costs. The Company has a growing global IP portfolio that includes global design patents, utility patents, registrations, and trade secrets. It has additional applications pending in the US and internationally (PCT).
Excellent opportunity for a life sciences company to capitalize on the Company's growing IP portfolio through broader manufacturing and distribution capabilities, or for a drug development company to use the patented technology to create a more efficient and cost-effective drug development process. The potential buyer should have experience in the life sciences industry with the ability to manage a global IP portfolio of biotech related products.
The Company is currently in a leased space in a research oriented area. The Company and its intellectual property are relocatable.
The Company sells to both national and international pharmaceutical companies and distributors and is currently focused on the pharmaceutical drug metabolism segment. The global market for predictive toxicology is expected to be $9.9 Billion in 2017 (comprised of cosmetics, pharmaceuticals, and chemical), while the global microfluidics device market is expected to reach $5.2 Billion in 2019. There is significant opportunity to expand into the environmental toxicant, skin model and cosmetic inflammation, pesticide and fertilizer toxicant and chemical toxicant testing markets.
While there are several products that attempt to address the inadequate in vitro toxicity testing capability, according to a third-party research firm, none of these products appear to represent a significant competitive threat to the Company's unique and patented product.
Seeking company with manufacturing, distribution or drug development capabilities that can capitalize on Company's growing global IP portfolio.
Will train for 4 weeks @ no cost. The Company's main product is a proprietary fluidic culture system, which improves pharmaceutical and biotechnology companies' ability to predict human responses to drug compounds that they are developing. The potential buyer should have experience in the life sciences industry with the ability to manage a global IP portfolio of biotech related products.